Alterations of bone metabolism of patients with primary and platinum-sensitive recurrent tuboovarian carcinoma induced by platinum-based chemotherapy with and without bevacizumab

被引：0
|
作者：
Kurbacher, C. M. [1 ]
Herz, S. [1 ]
Kurbacher, A. T. [1 ]
Rhau, W. [1 ]
Kurbacher, J. A. [1 ]
机构：
[1] Gynecol Ctr Bonn Friedenspl, Bonn, Germany
来源：
GYNECOLOGIC ONCOLOGY | 2019年 / 154卷
关键词：
D O I：
10.1016/j.ygyno.2019.04.178
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1247
引用
收藏
页码：75 / 75
页数：1
相关论文
共 50 条
  • [31] Radiation therapy to the pelvis for patients with metastatic disease treated with platinum-based chemotherapy and bevacizumab
    Wiley, R. L.
    Bondre, I. L.
    Jalloul, R.
    Klopp, A. H.
    Taylor, J. S.
    Ramondetta, L. M.
    GYNECOLOGIC ONCOLOGY, 2020, 159 : 197 - 197
  • [32] EFFECT OF PRIOR BEVACIZUMAB THERAPY IN PATIENTS WITH PLATINUM-SENSITIVE RECURRENT OVARIAN CARCINOMA (ROC) IN THE PHASE 3 STUDY ARIEL3
    Oza, A.
    Coleman, R. L.
    Lorusso, D.
    Aghajanian, C.
    Oaknin, A.
    Dean, A.
    Colombo, N.
    Weberpals, J. I.
    Clamp, A.
    Scambia, G.
    Leary, A.
    Holloway, R. W.
    Amenedo Gancedo, M.
    Fong, P. C.
    Goh, J. C.
    O'Malley, D. M.
    Banerjee, S.
    Goble, S.
    Cameron, T.
    Ledermann, J. A.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 : 45 - 46
  • [33] Efficacy of PARPi monotherapy and the impact of subsequent platinum-based chemotherapy in BRCA1/2 mutant ovarian cancer patients with secondary platinum-sensitive relapse
    Song, K.
    Ma, Y.
    Li, N.
    Bu, H.
    Huang, Y.
    Jin, C.
    Wen, H.
    Feng, S.
    Zhang, H.
    Wu, L.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S795 - S795
  • [34] A PHASE III RANDOMIZED CONTROLLED TRIAL OF SECONDARY CYTOREDUCTIVE SURGERY (SCS) FOLLOWED BY PLATINUM-BASED CHEMOTHERAPY (PC) PLATINUM-SENSITIVE, RECURRENT OVARIAN CANCER (PSOC) - SURGICAL PARAMETERS
    Coleman, R. L.
    Enserro, D.
    Herzog, T. J.
    Sabbatini, P.
    Armstrong, D. K.
    Kim, B.
    Fujiwara, K.
    Walker, J. L.
    Spirtos, N.
    Flynn, P. J.
    Secord, A. Alvarez
    Cohn, D. E.
    Brady, M. F.
    Mannel, R. S.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 : 52 - 52
  • [35] Platinum-Based Chemotherapy Plus Cetuximab in Patients With Recurrent or Metastatic Nasopharyngeal Cancer
    Ueda, Y.
    Tahara, M.
    Fujisawa, T.
    Enokida, T.
    Okano, S.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 100 (05): : 1371 - 1371
  • [36] HIPEC ROC I: A phase I study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum-based chemotherapy in patients with platinum-sensitive recurrent epithelial ovarian cancer
    Zivanovic, Oliver
    Abramian, Alina
    Kullmann, Maximilian
    Fuhrmann, Christine
    Coch, Christoph
    Hoeller, Tobias
    Ruehs, Hauke
    Keyver-Paik, Mignon Denise
    Rudlowski, Christian
    Weber, Stefan
    Kiefer, Nicholas
    Poelcher, Martin L.
    Thiesler, Thore
    Rostamzadeh, Babak
    Mallmann, Michael
    Schaefer, Nico
    Permantier, Maryse
    Latten, Sandra
    Kalff, Joerg
    Thomale, Juergen
    Jaehde, Ulrich
    Kuhn, Walther C.
    INTERNATIONAL JOURNAL OF CANCER, 2015, 136 (03) : 699 - 708
  • [37] Trends in adverse events over the treatment course in patients on chemotherapy for recurrent platinum-sensitive ovarian cancer
    Francis, Katherine E.
    Lee, Chee Khoon
    Gebski, Val
    Lord, Sally
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 : 120 - 120
  • [38] OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
    Aghajanian, Carol
    Blank, Stephanie V.
    Goff, Barbara A.
    Judson, Patricia L.
    Teneriello, Michael G.
    Husain, Amreen
    Sovak, Mika A.
    Yi, Jing
    Nycum, Lawrence R.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (17) : 2039 - 2045
  • [39] Prognostic Significance of Hemoglobin Levels in Patients with Primary Epithelial Ovarian Carcinoma Undergoing Platinum-based Chemotherapy
    Pongsanon, Khemmawan
    Benjapibal, Mongkol
    Ruengkhachorn, Irene
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2011, 12 (01) : 131 - 136
  • [40] A phase III randomized controlled trial of secondary surgical cytoreduction (SSC) followed by platinum-based combination chemotherapy (PBC), with or without bevacizumab (B) in platinum-sensitive, recurrent ovarian cancer (PSOC): A NRG Oncology/Gynecologic Oncology Group (GOG) study.
    Coleman, Robert L.
    Enserro, Danielle
    Spirtos, Nick
    Herzog, Thomas J.
    Sabbatini, Paul
    Armstrong, Deborah Kay
    Kim, Byoung
    Fujiwara, Keiichi
    Walker, Joan L.
    Flynn, Patrick J.
    Secord, Angeles Alvarez
    Cohn, David E.
    Brady, Mark F.
    Mannel, Robert S.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345